Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.42 |
| ▸ | CA2 | P00918 | 3/20 | 0.42 |
| ▸ | CA12 | O43570 | 2/20 | 0.42 |
| ▸ | CA7 | P43166 | 2/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.42 |
| ▸ | PPARD | Q03181 | 1/20 | 0.38 |
| ▸ | PPARA | Q07869 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3971946 | 0.90 | OPRK1 (0.46) | ACHE | |
| SCHEMBL6755788 | 0.87 | CA1 (0.38) | CA1CA2CA12CA7CA14 | |
| SCHEMBL3975314 | 0.84 | PPARD (0.39) | PPARDPPARA | |
| SCHEMBL3974229 | 0.82 | CA1 (0.51) | CA1CA2CA12CA7CA14 | |
| SCHEMBL3848326 | 0.81 | PPARD (0.41) | PPARDPPARA | |
| SCHEMBL13598351 | 0.81 | PPARD (0.41) | PPARDPPARA | |
| SCHEMBL3847852 | 0.81 | PPARD (0.41) | PPARDPPARA | |
| SCHEMBL3973524 | 0.76 | MTNR1A (0.51) | CA1CA2CA12CA7CA14 | |
| SCHEMBL3848313 | 0.75 | HTR1D (0.40) | CA1CA2PPARDPPARAACHE | |
| SCHEMBL3977709 | 0.74 | PPARD (0.35) | PPARDPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1554240-B1 | SUBSTITUTED TETRALINS AND INDANES AND THEIR USE | JANSSEN PHARMACEUTICA NV (BE) | 2009-05-06 | — | — | EP | disclosed |
| US-7351857-B2 | Methods of using substituted tetralins and indanes | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-04-01 | — | — | US | disclosed |
| US-20060247314-A1 | Substituted tetralins and indanes | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-11-02 | — | — | US | disclosed |
| US-20060094786-A1 | Treating syndrome X with substituted tetralins and indanes | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-05-04 | — | — | US | disclosed |
| US-20060074130-A1 | Methods of using substituted tetralins and indanes | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-04-06 | — | — | US | disclosed |
| EP-1569897-A1 | SUBSTITUTED TETRALINS AND INDANES | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-09-07 | — | — | EP | disclosed |
| EP-1556344-A1 | TREATING SYNDROME X WITH SUBSTITUTED TETRALINS AND INDANES | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-07-27 | — | — | EP | disclosed |
| EP-1554240-A1 | SUBSTITUTED TETRALINS AND INDANES AND THEIR USE | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-07-20 | — | — | EP | disclosed |
| US-20040171680-A1 | Treating Syndrome X with substituted tetralins and indanes | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-09-02 | — | — | US | disclosed |
| US-20040167211-A1 | Methods of using substituted tetralins and indanes | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-08-26 | — | — | US | disclosed |
| US-20040162352-A1 | Treating syndrome X with substituted tetralins and indanes | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-08-19 | — | — | US | disclosed |
| WO-2004037779-A1 | SUBSTITUTED TETRALINS AND INDANES AND THEIR USE | JANSSEN PHARMACEUTICA, N.V. (BE) | 2004-05-06 | — | — | WO | disclosed |
| WO-2004037777-A1 | TREATING SYNDROME X WITH SUBSTITUTED TETRALINS AND INDANES | JANSSEN PHARMACEUTICA, N.V. (BE) | 2004-05-06 | — | — | WO | disclosed |
| WO-2004037778-A1 | SUBSTITUTED TETRALINS AND INDANES | JANSSEN PHARMACEUTICA, N.V. (BE) | 2004-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094786-A1 | Treating syndrome X with substituted tetralins and indanes | PPARG, PPARA, PPARD | CA1 4769/4885CA2 3706/4885CA12 4828/4885 |
| US-20060074130-A1 | Methods of using substituted tetralins and indanes | PPARA, PPARG, PPARD | CA1 4250/4885CA2 2558/4885CA12 4354/4885 |
| US-20040171680-A1 | Treating Syndrome X with substituted tetralins and indanes | PPARG, PPARA, PPARD | CA1 4769/4885CA2 3706/4885CA12 4828/4885 |
| US-20040162352-A1 | Treating syndrome X with substituted tetralins and indanes | PPARG, PPARA, PPARD | CA1 4769/4885CA2 3706/4885CA12 4828/4885 |
| US-20040167211-A1 | Methods of using substituted tetralins and indanes | PPARA, PPARG, PPARD | CA1 4250/4885CA2 2558/4885CA12 4354/4885 |
| US-20060247314-A1 | Substituted tetralins and indanes | PPARA, PPARG, PPARD | CA1 4753/4885CA2 3976/4885CA12 4830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.